We next investigated the impact of somatic ERCC2 mutations identified in bladder cancer cohorts (Figure 2B) on cell fitness in the TP53 KO (Figure 2D) and WT cell lines (Supplemental Figure 2D). The gene discussed is TP53; the disease is urinary bladder cancer.